Complement activation profiles in patients with immune checkpoint inhibitor-associated neuromuscular immune-related adverse events.

J Neurol · 2025 · PMC12162679 · PMID 40506552

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

did not reach statistical significancep = 0.06so close (0.05 < p ≤ 0.1)

While there were no statistically significant differences in progression-free survival or tumor response rates between the groups, more patients with irMyositis died from irAE-n, although this difference did not reach statistical significance ( p = 0.06).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.